BALAD-2 Emerges as the Most Accurate Prognostic Model in Hepatocellular Carcinoma: Results from a Biobank-Based Cohort Study.

ABSTRACT: Background/Objectives: Accurate prognostication of hepatocellular carcinoma (HCC) remains essential for treatment selection and risk stratification. This study aimed to compare the prognostic performance of individual serum biomarkers and composite scoring models, including GALAD, BALAD, BALAD-2, GAAP, ASAP, the Doylestown algorithm, and aMAP, using data from a biobank-based HCC cohort. Methods: This study enrolled 186 patients with confirmed HCC diagnosed between 2019 and 2024. Serum biomarkers (AFP, AFP-L3%, DCP) and composite models were evaluated for their association with overall survival (OS). Prognostic performance was assessed using time-dependent area under the receiver operating characteristic curve (AUROC) at 1-, 2-, 3-, and 5-year intervals and Harrel's concordanc

SUBMITTER: Demirtas CO 

PROVIDER: S-EPMC12610203 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature